National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Adverse Drug Events (ADE) (1)
- Adverse Events (1)
- (-) Cancer (7)
- Cancer: Breast Cancer (1)
- Cancer: Prostate Cancer (1)
- Care Management (1)
- Chronic Conditions (1)
- Evidence-Based Practice (1)
- Guidelines (1)
- (-) Medication (7)
- Medication: Safety (1)
- Men's Health (1)
- Patient Adherence/Compliance (1)
- Patient Safety (1)
- Prevention (1)
- Primary Care (1)
- Provider (1)
- Provider: Physician (1)
- Quality of Life (1)
- Treatments (1)
- U.S. Preventive Services Task Force (USPSTF) (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 7 of 7 Research Studies DisplayedCole AL, Jazowski SA, Dusetzina SB
Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia.
Investigators compared adherence to tyrosine kinase inhibitors (TKIs) between patients with chronic myeloid leukemia (CML) who initiated branded or generic imatinib using MarketScan commercial claims data. They found that patients initiating generic imatinib achieved clinically significant improvements in adherence to TKI therapy relative to branded drug users, presumably due to lower out-of-pocket costs. Given the importance of optimal adherence in CML, considering barriers to adherence when selecting initial treatment may improve long-term medication adherence.
AHRQ-funded; HS000032.
Citation: Cole AL, Jazowski SA, Dusetzina SB .
Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia.
Pharmacoepidemiol Drug Saf 2019 Nov;28(11):1529-33. doi: 10.1002/pds.4893..
Keywords: Patient Adherence/Compliance, Medication, Chronic Conditions, Cancer
Crossnohere NL, Richardson DR, Reinhart C
Side effects from acute myeloid leukemia treatment: results from a national survey.
Acute myeloid leukemia (AML) is experiencing a therapeutic renaissance due to the heightened biomedical understanding of AML and patient-focused drug development (PFDD). Many AML patients now live long-term with the side effects of treatment. This study documents the prevalence and severity of AML treatment-related side effects. This study documents the prevalence and severity of AML treatment-related side effects.
AHRQ-funded; HS000032.
Citation: Crossnohere NL, Richardson DR, Reinhart C .
Side effects from acute myeloid leukemia treatment: results from a national survey.
Curr Med Res Opin 2019 Nov;35(11):1965-70. doi: 10.1080/03007995.2019.1631149..
Keywords: Adverse Drug Events (ADE), Adverse Events, Cancer, Medication, Quality of Life
Nelson HD, Fu R, Zakher B
Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force.
The purpose of this paper was to update the 2013 US Preventive Services Task Force systematic review on medications to reduce risk of primary (first diagnosis) invasive breast cancer in women. Investigators abstracted data on methods, participant characteristics, eligibility criteria, outcome ascertainment, and follow-up; individual trial results were combined using a profile likelihood random-effects model. Results showed that tamoxifen, raloxifene, and aromatase inhibitors were associated with lower risk of primary invasive breast cancer in women but also were associated with adverse effects that differed between medications. Risk stratification methods to identify patients with increased breast cancer risk demonstrated low accuracy.
AHRQ-funded; 290201500009I.
Citation: Nelson HD, Fu R, Zakher B .
Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force.
JAMA 2019 Sep 3;322(9):868-86. doi: 10.1001/jama.2019.5780..
Keywords: Cancer: Breast Cancer, Cancer, Medication, U.S. Preventive Services Task Force (USPSTF), Evidence-Based Practice, Guidelines, Prevention, Primary Care
Caram MEV, Kaufman SR, Modi PK
Adoption of abiraterone and enzalutamide by urologists.
The purpose of this study was to investigate the adoption of abiraterone and enzalutamide by urologists. Abiraterone and enzalutamide are oral therapies approved for the treatment of metastatic castration-resistant prostate cancer, a disease most commonly treated by medical oncologists. The investigators found that urologists are increasingly prescribing oral therapies for metastatic castration-resistant prostate cancer. They suggest that understanding the distribution of urologists specializing in castration-resistant prostate cancer therapeutics will help guide future interventions to optimize the care for this important patient population.
AHRQ-funded; HS025707.
Citation: Caram MEV, Kaufman SR, Modi PK .
Adoption of abiraterone and enzalutamide by urologists.
Urology 2019 Sep;131:176-83. doi: 10.1016/j.urology.2019.05.012..
Keywords: Cancer, Cancer: Prostate Cancer, Care Management, Medication, Men's Health
Alpert A, Jacobson M
Impact of oncology drug shortages on chemotherapy treatment.
The investigators examined outpatient chemotherapy use during shortage periods relative to the months before and after a shortage for newly diagnosed patients. For most drugs, little impact of shortages on either the fraction of patients receiving that drug or the quantity provided was found. The investigators discussed potential explanations for these counterintuitive findings, including potential limitations of current drug shortage reporting methods.
AHRQ-funded; HS022741.
Citation: Alpert A, Jacobson M .
Impact of oncology drug shortages on chemotherapy treatment.
Clin Pharmacol Ther 2019 Aug;1-6(2):415-21. doi: 10.1002/cpt.1390..
Keywords: Cancer, Treatments, Medication
Mitchell AP, Winn AN, Lund JL
Evaluating the strength of the association between industry payments and prescribing practices in oncology.
Financial relationships between physicians and the pharmaceutical industry are common, but factors that may determine whether such relationships result in physician practice changes are unknown. This study evaluated physician use of orally administered cancer drugs for four cancers and whether practice setting at a National Cancer Institute (NCI)-designated Comprehensive Cancer Center, receipt of payments for purposes other than education or research (compensation payments), maximum annual dollar value received, and institutional conflict-of-interest policies were associated with the strength of the payment-prescribing association.
AHRQ-funded; HS000032.
Citation: Mitchell AP, Winn AN, Lund JL .
Evaluating the strength of the association between industry payments and prescribing practices in oncology.
Oncologist 2019 May;24(5):632-39. doi: 10.1634/theoncologist.2018-0423..
Keywords: Cancer, Medication, Provider: Physician, Provider
Nonzee NJ, Luu TH
The drug shortage crisis in the United States: impact on cancer pharmaceutical safety.
This study examined the drug short crisis in the United States and its impact on cancer pharmaceutical safety. These shortages present safety risk for patients and adversely affect patient outcomes. There are multiple drivers of this problem including manufacturing disruptions, raw material shortages, regulatory issues, market dynamics and limited financial incentives for off-patent drugs.
AHRQ-funded; HS000046.
Citation: Nonzee NJ, Luu TH .
The drug shortage crisis in the United States: impact on cancer pharmaceutical safety.
Cancer Treat Res 2019;171:75-92. doi: 10.1007/978-3-319-43896-2_6..
Keywords: Cancer, Medication, Medication: Safety, Patient Safety